A Phase II, Dose Escalation Evaluation of the Pharmacokinetic and Hemodynamic Effects of Carperitide in Subjects With Congestive Heart Failure

NCT00259038 Phase 2 COMPLETED

The study will evaluate the safety and efficacy of intravenous infusion of carperitide using pressure measurements inside the heart and great vessels and measuring carperitide concentration in the blood.

Details

Lead sponsor	Daiichi Sankyo
Phase	Phase 2
Status	COMPLETED
Enrolment	162
Start date	2004-01
Completion	2006-02

Conditions

• Heart Failure, Congestive
• Heart Decompensation
• Left Ventricular Failure
• Myocardiopathies
• Systolic or Diastolic Left Ventricular Dysfunction

Interventions

• Carperitide
• Placebo

Primary outcomes

• Change from baseline in pulmonary capillary wedge pressure (PCWP) — at 3 hours following initiation of study drug infusion

Countries

United States, Canada